Alerta

CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME

Resumen de: US12263241B1

The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.

CROSSLINKED POLYSACCHARIDE NANOPARTICLES

Resumen de: WO2025114613A1

Crosslinked polysaccharide nanoparticles The present invention relates to cross-linked polysaccharide nanoparticles, which can be used as drug delivery systems. The herein disclosed cross-linked polysaccharide nanoparticles are obtained via an emulsion cross-linking process. The careful choice of the surfactants used for forming the emulsion allows to reliably obtain small particles with a low polydispersity. Moreover, these particles are stable in saline solutions. The cross-linked polysaccharide nanoparticles can be loaded with proteinaceous fibrinolytic or thrombolytic agents and could be used as drug delivery systems for the treatment of thrombosis.

IONIZABLE LIPID NANOPARTICLES

Resumen de: WO2025114520A1

The present invention relates to ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety. The ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety, disclosed herein, are useful in delivering an agent to a cell or in transfecting a cell, especially for gene therapy or for gene editing.

COMPOUND COMPRISING EXTRACELLULAR VESICLES DERIVED FROM BIOLOGICAL MATERIAL NOT BELONGING TO THE ANIMAL KINGDOM AND ITS APPLICATIONS

Resumen de: WO2025114909A1

Compound for relieving inflammation in an organism comprising nanometer-sized extracellular vesicles (EVs) derived from biological material not belonging to the animal kingdom, but preferably belonging to the plant and fungi kingdoms, and loaded with a bioactive or a mixture of bioactives, preferably of plant origin.

OXIDATION-RESPONSIVE CATIONIC WATER-SOLUBLE PILLARARENE, AND PREPARATION METHOD AND USE

Resumen de: EP4818181A1

Disclosed are an oxidation-responsive water-soluble cationic pillararene, and a preparation method and application thereof, the oxidation-responsive water-soluble cationic pillararene is a cyclic small-molecule nucleic acid vector, and is obtained by quaternization reaction of 4-methylborate and tertiary amine-modified pillararene. According to the invention, a delivery vector with a high positive charge density is obtained through small molecule synthesis, the delivery vector is capable of being tightly combined with negatively charged nucleic acid substances to form a nano-composite, and after the nano-composite enters cells, vector positive charges fall off to release the nucleic acid substances in an oxidation environment, and nucleic acid information is efficiently expressed. The delivery vector has the characteristics of simplicity and convenience in synthesis, high delivery efficiency and good biological safety, and has a good application prospect.

BIFUNCTIONAL COMPOSITE MOLECULE OF ANTI-TUMOR ANTIBODY AND INTERLEUKIN-15 PRECURSOR, AND USE OF BIFUNCTIONAL COMPOSITE MOLECULE

Resumen de: EP4818212A1

0001 The present inventions provides a complex molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and use thereof in the manufacture of a medicament for treating cancer. The complex molecule comprises an antitumor antibody domain, a linker, and pro-IL-15, wherein the antitumor antibody domain and pro-IL-15 are linked by the linker. The antitumor antibody domain is a complete antibody, a nanobody, or an antigen-binding fragment thereof against an immune checkpoint molecule, a tumor antigen molecule, or an immune activation molecule. The linker is a polypeptide linker or a non-peptide linker. The pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, a linking peptide, and optionally an IL-15Rβ extracellular domain, wherein the IL-15Rβ extracellular domain, IL-15, and the IL-15Rα sushi domain are linked by linking peptides.

SUPPLEMENTATION OF LIVER ENZYME EXPRESSION

Resumen de: WO2025117858A1

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

METHOD OF ENCAPSULATING MYCOBACTERIUM BOVIS BCG VACCINE BACILLI IN AN ALGINATE CARRIER TO COMBAT HELICOBACTER PYLORI INFECTION

Resumen de: EP4817599A1

0001 The invention relates to a method of manufacturing microparticles containing Mycobacterium bovis BCG vaccine bacilli encapsulated in an alginate carrier, intended for combating Helicobacter pylori infection, characterised in that an aqueous solution of a non-ionic copolymeric surfactant (C<3>H<6>O.C<2>H<4>O) and/or a solution of chitosan in 1% acetic acid, and a suspension of live M. bovis BCG in 1 mL of saline solution with a BCG density of 3×10<9> CFU/mL, and then subjected to a microencapsulation procedure by adding the above-mentioned solutions dropwise, using a 2 mL syringe, to a vessel containing a 0.5% calcium chloride solution, at room temperature on a magnetic stirrer for 1 hour. After one hour, the microcapsules are drained using a laboratory sieve and rinsed with sterile distilled water, using chitosans with a molecular weight in the range of 50.000-190.000 g/mol or 190.000-310.000 g/mol or 310.000-375.000 g/mol, with the concentration of the polymer solution used to prepare the alginate microcapsules being 2% v/v for alginate, 1% v/v for chitosan and 12 600 g/mol for the non-ionic copolymer surfactant (C<3>H<6>O.C<2>H<4>O)x.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025117816A1

Disclosed herein are lipid nanoparticles (LNPS) and pharmaceutical compositions and vaccines comprising same. Also disclosed herein are methods of administering an LNP composition, pharmaceutical compositions, and vaccines described herein for preventing an infectious disease and/or for immunizing a subject or for delivering a payload to a cell in the central nervous system (CNS) of a subject. Also provided are methods for treating and/or preventing a CNS disease.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF AND METHOD FOR QUANTIFYING AN AMOUNT OF CAPPED MESSENGER RNA

Resumen de: WO2025117815A1

Provided are lipid nanoparticles compositions comprising a payload, a helper lipid, a sterol, a PEG-lipid, an ionizable lipid, a permanently cationic lipids. Also provided herein are a method of delivering a payload to a cell in a lung of a subject by intravenous administration and a method for treating and/or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.

PROCESS FOR MANUFACTURING LIPID NANOPARTICLES

Resumen de: WO2025117969A1

The present application provides methods for manufacturing lipid nanoparticles. The present disclosure provides methods of preparing empty lipid nanoparticles (empty LNPs). The present disclosure provides methods of preparing loaded lipid nanoparticles (loaded LNPs) associated with a nucleic acid. Empty and loaded LNP compositions prepared by the subject methods are also provided. There is provided a homogeneous LNP composition of empty or loaded LNPs of particularly favorable average particle size and poly dispersity index.

RADIOPAQUE NANOPARTICLES FOR MEDICAL IMAGING

Resumen de: US20250177577A1

The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.

HYBRID PARTICLES COMPRISING A CROSS-LINKED POLYSACCHARIDE MATRIX AND METAL OXIDE NANOPARTICLES

Resumen de: WO2025114612A1

Hybrid particles comprising a cross-linked polysaccharide matrix and metal oxide nanoparticles The invention relates to a method of manufacturing hybrid particles comprising a matrix of cross-linked polysaccharide and metal oxide nanoparticles embedded therein. It has been found that hybrid particles with low polydispersity and a high load of metal oxide nanoparticles could be obtained when non-coated metal oxide nanoparticles are used. Aggregation of the non-coated metal oxide nanoparticles could be controlled to achieve said polydispersity and load. The hybrid particles of the invention, when the metal oxide is a magnetic and photothermal metal oxide, could act on the thrombosis via a combination of thermal and mechanical action, through light and magnetic stimulation, and would be targeted to the occluded vessel by an external permanent magnet.

NANOPARTICLES COMPRISING SIROLIMUS AND ALBUMIN, PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS ADMINISTRATION, COMPRISING SAME, AND PREPARATION METHOD THEREFOR

Resumen de: EP4817601A1

The present disclosure relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition for subcutaneous administration comprising the same, and a method for preparing the same. When the preparation method of the present disclosure is used, nanoparticles comprising sirolimus and albumin having excellent particle size distribution maintenance stability can be prepared, and the prepared nanoparticles can be prepared into a pharmaceutical composition suitable for subcutaneous injection, thereby improving an increase in an administration dose and the convenience of medication administration.

GLUCOSE-TRIGGERED GELATION OF SUPRAMOLECULAR PEPTIDE NANOCOILS WITH GLUCOSE-BINDING MOTIFS

Resumen de: WO2025117822A1

Described herein are self-assembled peptides and hydrogels comprising self-assembled peptides and glucose. Exemplary hydrogels comprising self-assembled peptides and glucose may be used to encapsulate glucagon and/or a glucagon analogue. Hydrogels with glucagon and/or a glucagon analogue encapsulated therein may be used to treat hypoglycemia and related disorders in subjects in need thereof.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025117817A1

Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs), the LNP comprising at least two selective organ targeting (SORT) lipids and/or at least six lipids. Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.

一种分阶段实现溶酶体规避与靶向的载药脑部递送载体及其应用

Resumen de: CN122849186A

本发明公开了一种分阶段实现溶酶体规避与靶向的载药脑部递送载体，其以叶酸修饰的聚合物纳米材料为载药内核，以膜融合脂质体与人脑微血管内皮细胞膜融合形成的仿生杂化膜为包覆层。该载药脑部递送载体跨越血脑屏障时，可通过膜融合机制规避传统溶酶体胞内转运途径，有效避免药物载体在脑微血管内皮细胞内发生溶酶体滞留与降解，保障载药内核高效穿透脑部血管抵达脑实质；随后，载药内核可借助表面特异性配体叶酸精准靶向脑肿瘤细胞，并于其溶酶体内释放药物，一方面有效削弱肿瘤细胞溶酶体的细胞保护效应，另一方面可直接破坏肿瘤细胞溶酶体，引发其功能紊乱和内容物外泄，诱导肿瘤细胞死亡，从多维度显著提升脑肿瘤治疗效果。

一种两性离子聚合物及包含其的脂质组合物和用途

Resumen de: CN122854573A

本公开涉及靶向递送脂质技术领域，具体涉及一种两性离子聚合物及包含其的脂质组合物和用途。本公开提供的靶向脾的两性离子聚合物具有式(I)所示的结构，可用作RNA靶向递送，能够显著增强mRNA药物对于脾靶向效果。

一种眼后段药物递送的脂质体、包含脂质体的滴眼液及其应用

Resumen de: CN122849159A

本申请涉及生物医药及创新制剂开发技术领域，具体涉及一种眼后段药物递送的脂质体、包含脂质体的滴眼液及其应用。所述脂质体包括脂质体内核和外层短肽修饰层，所述的脂质体内核包括脂质双层膜，所述短肽包括Gly‑Ser。所述脂质体内核中可以稳定包载治疗剂，将其制备为纳米滴眼液。所述的纳米滴眼液在不影响眼表屏障功能的基础上显著提升治疗剂的跨眼后段穿透性，并且显著提升对于眼病的治疗效果。

一种仿生型唑类可电离脂质化合物及其制备方法和应用

Resumen de: CN122854130A

本发明涉及一种仿生型唑类可电离脂质化合物及其制备方法和应用，仿生型唑类可电离脂质化合物结构仿天然磷脂设计，在咪唑环或噻唑环的4位与5位上分别修饰有1,2‑二酰甘油酯，并在咪唑环或噻唑环2位上修饰有不同烷基链长的含氮基团，形成具备四条柔性脂链的四酰基唑类仿生脂质。仿生型唑类可电离脂质化合物与治疗性药物及其他脂质辅料混合，能够制备得到治疗性药物被装载在内的载药脂质纳米颗粒，作为药物递送系统用于脑靶向药物的制备；仿生型唑类可电离脂质化合物具备调控血脑屏障开放‑闭合的功能，能够实现血脑屏障可逆开放；所形成的药物递送系统能够穿越血脑屏障并较好地实现所装载治疗性药物的脑靶向递送。

一种葛根芩连汤果胶-壳聚糖纳米粒及制备方法和应用

Resumen de: CN122849189A

本发明属于中药制剂与纳米递送技术领域，具体涉及一种葛根芩连汤果胶‑壳聚糖纳米粒及制备方法和在炎症性肠病相关疾病模型中的应用。采用离子凝胶化法，以壳聚糖为载体，通过带负电的三聚磷酸钠作为交联剂，利用静电相互作用使葛根芩连汤负载于壳聚糖形成纳米粒；再采用果胶对所得纳米粒进行表面包覆，得到葛根芩连汤果胶‑壳聚糖纳米粒。与现有技术相比，本发明工艺温和、步骤简便、重复性好，适用于口服给药及结肠靶向制剂开发。

一种负载小分子抗肿瘤药物和光敏剂的功能化仿生纳米粒及其制备方法和应用

Resumen de: CN122849184A

本发明提供了一种负载小分子抗肿瘤药物和光敏剂的功能化仿生纳米粒及其制备方法和应用。该仿生纳米给药系统以TPGS偶联光敏剂Ce6为骨架，包载芫花酯甲（YHC）和黄芪甲苷（AS‑IV），形成YA/Ce6‑TPGS纳米复合物；随后在表面包覆NK细胞膜，构建YA/Ce6‑TPGS@NK功能化仿生靶向递药系统，具有粒径小、载药量和包封率高等特点。系统通过保留NK细胞膜表面的多种蛋白实现对癌细胞的识别与靶向，并降低载体免疫原性，增强循环稳定性，实现精准递送；TPGS‑Ce6载体经光照发挥光动力学杀伤效应，包载的YHC与AS‑IV在肿瘤组织释放，发挥化学抗肿瘤作用，实现化疗与光动力疗法协同抗肿瘤作用。体内外实验表明，其具有显著的抗肿瘤活性和良好生物相容性，并呈现良好的肿瘤靶向性以及潜在的逆转耐药能力。

一种载药磁性过氧化锌纳米颗粒及其制备方法和应用

Resumen de: CN122849187A

本发明提供一种载药磁性过氧化锌复合纳米颗粒及其制备方法和应用，属于癌细胞诊疗剂领域。该制备方法先在碳化铁纳米颗粒表面原位生长过氧化锌，再借助过氧化锌的表面孔隙负载抗癌药物，并利用DSPE‑PEG‑FA进行功能化修饰，以提高其主动靶向和生物安全性。该方法条件温和，步骤简便，所得复合纳米颗粒尺寸均一，稳定性良好，且兼具优异的磁响应性、磁共振成像能力和载药性能，能够显著增强对癌细胞的治疗效果。

一种基于转谷氨酰胺酶催化交联的工程化细胞、制备方法及其应用

Resumen de: CN122849183A

本发明公开了一种基于转谷氨酰胺酶催化交联的工程化细胞、制备方法及其在免疫性溶血性疾病中的应用；该方法包括：（1）合成化合物I；（2）取细胞悬液，向其中加入化合物I，反应完成后，分离得到化合物I锚定的细胞；（3）合成化合物II和III；（4）向化合物I锚定的细胞悬液中加入化合物II和III，混匀反应后，分离得到聚糖水凝胶包覆的工程化细胞制品。本发明方法制备的工程化细胞制品能够有效掩蔽细胞表面多种抗原表位，用于制备抗原掩蔽型工程化红细胞，使得输注后红细胞在免疫性溶血疾病状态下的体内循环半衰期得以显著延长。

基于香豆素衍生物的声动力治疗仿生纳米颗粒及其抗肿瘤应用

Nº publicación: CN122854163A 02/10/2026

Solicitante:

华中农业大学

Resumen de: CN122854163A

本发明涉及一种基于香豆素结构的新型有机声敏剂DBCA及其仿生纳米颗粒在肿瘤声动力治疗中的应用。本发明所述声敏剂具有结构简单、原料易得、合成路线短、成本低等优势，在超声作用下能够高效产生ROS，实现对肿瘤细胞的杀伤作用，并具有极低光毒性和良好生物安全性。本发明进一步提供以DSPE‑PEG2000将DBCA包裹形成的纳米颗粒DBCA@PEG，随后利用放疗诱导的肿瘤细胞膜包覆并可联合免疫佐剂获得仿生纳米颗粒DBCA@RM。该仿生结构赋予纳米颗粒同源靶向性，延长肿瘤内驻留时间，同时带有肿瘤相关抗原和固有免疫刺激特性，有助于增强声动力治疗及免疫激活效应。本发明的纳米制剂可应用于肿瘤精准治疗、声动力治疗等领域，具有良好的应用前景。